INTEGRAL MOLECULAR INC — Department of Health and Human Services SBIR Phase II: 400

Description

ABSTRACT Membrane proteins control the flow of informationnutrientsand signals through the cell membraneand are the targets forof FDA approved drugsMonoclonal antibodiesMAbsthat target membrane proteins can be exceptionally valuable in researchdiagnosticand therapeutic applicationsbut for the vast majority of membrane proteins there are either no MAbs at all or only poor quality antibodies with limited applicationThe need for high quality MAbs against membrane proteins has been recognized by industry and the NIHbut efforts to identify such MAbs are limited by the difficulty in expressing and purifying membrane proteins in exogenous systems and by conventional MAb isolation strategies that focus on one target at a timeA novel approach to identify membrane protein MAbs in a high throughput manner is needed to derive MAbs against the entire human membrane proteomeHere we propose a technology that can be used to rapidly isolate high quality MAbs against membrane proteins to fulfill this unmet need PROJECT NARRATIVE This proposal will contribute to public health and the cure of human disease by isolating the largest collection of high quality MAbs against membrane proteins currently availableMAbs that target membrane proteins can be exceptionally valuable in researchdiagnosticand therapeutic applicationsbut for the vast majority of membrane proteins there are either no MAbs at all or only poor quality antibodies with limited application